Notice Pursuant to the National Cooperative Research and Production Act of 1993-Cooperative Research Group on Clean Diesel V, 29718 [Z9-10358]
Download as PDF
<![CDATA[
29718
Federal Register / Vol. 74, No. 119 / Tuesday, June 23, 2009 / Notices
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 24, 2009.
Dated: June 15, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–14708 Filed 6–22–09; 8:45 am]
Springfield, Virginia 22152; and must be
filed no later than August 24, 2009.
Dated: June 15, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator/Deputy Chief
of Operation, Office of Diversion Control,
Drug Enforcement Administration.
[FR Doc. E9–14697 Filed 6–22–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Cooperative Research
Group on Clean Diesel V
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 13, 2009,
Austin Pharma LLC., 811 Paloma Drive,
Suite A, Round Rock, Texas 78665–
2402, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
BILLING CODE 1505–01–D
DEPARTMENT OF JUSTICE
I
I
I
II
II
II
II
II
II
II
II
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
Any other such applicant, and any
person who is presently, registered with
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
16:15 Jun 22, 2009
[FR Doc. Z9–10358 Filed 6–22–09; 8:45 am]
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Alphamethadol (9605) ..................
Nabilone (7379) ............................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Levo-alphacetylmethadol (9648) ..
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
VerDate Nov<24>2008
Correction
In notice document E9–10358
appearing on page 21403 in the issue of
May 7, 2009, make the following
correction:
On page 21403, in the first column, in
the second line from the bottom,
‘‘Auburn Hills, NI’’ should read
‘‘Auburn Hills, MI’’.
Jkt 217001
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations 1301.34(a),
this is notice that on May 18, 2009,
Aptuit, 10245 Hickman Mills Drive,
Kansas City, Missouri 64137, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Marihuana (7360), a basic class of
controlled substance listed in schedule
I.
The company plans to import a
finished pharmaceutical product
containing cannabis extracts in dosage
form for packaging for a clinical trial
study.
Any bulk manufacturer who is
presently, or is applying to be,
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 23, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import the basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: June 15, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–14693 Filed 6–22–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations 1301.34(a),
this is notice that on May 28, 2009,
Boehringer Ingelheim Chemicals, Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805, made application by
renewal to the Drug Enforcement
E:\FR\FM\23JNN1.SGM
23JNN1
]]>Agencies
[Federal Register Volume 74, Number 119 (Tuesday, June 23, 2009)]
[Notices]
[Page 29718]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: Z9-10358]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Cooperative Research Group on Clean Diesel V
Correction
In notice document E9-10358 appearing on page 21403 in the issue of
May 7, 2009, make the following correction:
On page 21403, in the first column, in the second line from the
bottom, ``Auburn Hills, NI'' should read ``Auburn Hills, MI''.
[FR Doc. Z9-10358 Filed 6-22-09; 8:45 am]
BILLING CODE 1505-01-D
